微小RNA-146a通过靶向JAK/STAT信号通路降低干细胞移植后树突状细胞MHC-II的表达
该研究在289例移植受者中发现,miR-146a基因G/C多态性导致miR-146a水平降低,与严重急性GVHD风险强烈相关。小鼠实验显示,造血系统miR-146a缺陷或输注受体型miR-146a-/-树突状细胞加重GVHD,而miR-146a模拟物转染的树突状细胞改善疾病。机制上,miR-146a缺失增强JAK2-STAT1通路活性,上调CIITA和MHCII表达;抑制JAK1/2或敲低CIITA可阻止GVHD加重。
要点
- 移植受者miR-146a基因G/C多态性致miR-146a水平降低,与严重急性GVHD风险强烈相关(n=289)。
- 小鼠中miR-146a缺陷或输注miR-146a-/-树突状细胞加重GVHD,miR-146a模拟物转染的树突状细胞改善疾病。
- 机制为miR-146a缺失增强JAK2-STAT1活性,上调CIITA和MHCII;抑制JAK1/2或敲低CIITA可阻止GVHD加重。
核心结论
- miR-146a多态性rs2910164可在异基因造血干细胞移植前识别GVHD高风险患者。
- miR-146a通过抑制促炎JAK-STAT/CIITA/MHCII轴,作为受体型树突状细胞活化的核心调节因子,为选择性患者早期抑制JAK1/2提供科学依据。
研究设计与样本
- 研究纳入289例移植受者分析miR-146a基因G/C多态性与严重急性GVHD风险的关联。
- 使用小鼠模型进行造血系统miR-146a缺陷、输注受体型miR-146a-/-树突状细胞及miR-146a模拟物转染树突状细胞的实验。
- 在患者中检测造血细胞miR-146a多态性rs2910164与单核细胞MHCII水平的关系。
主要发现
- 移植受者miR-146a基因G/C多态性导致miR-146a水平降低,与严重急性GVHD风险强烈相关(n=289)。
- 小鼠中造血系统miR-146a缺陷或输注受体型miR-146a-/-树突状细胞增强GVHD,而miR-146a模拟物转染的树突状细胞改善疾病。
- miR-146a缺失增强JAK2-STAT1通路活性,导致CIITA表达升高和树突状细胞MHCII水平增加。
- 在树突状细胞中抑制JAK1/2或敲低CIITA可阻止miR-146a-/-树突状细胞诱导的GVHD加重。
- 造血细胞携带miR-146a多态性rs2910164的患者单核细胞MHCII水平更高,可被JAK1/2抑制靶向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute Graft-versus-host disease (GVHD) is a major immunological complication after allogeneic hematopoietic cell transplantation and a better understanding of the molecular regulation of the disease could help to develop novel targeted therapies. Here we found that a G/C polymorphism within the human microRNA-146a (miR-146a) gene of transplant recipients, which causes reduced miR-146a levels, was strongly associated with the risk of developing severe acute GVHD (n=289). In mice, deficiency of miR-146a in the hematopoietic system or transfer of recipient-type miR-146a-/- dendritic cells (DCs) enhanced GVHD, while miR-146a mimic-transfected DCs ameliorated disease. Mechanistically, lack of miR-146a enhanced JAK2-STAT1 pathway activity, which led to higher expression of class II-transactivator (CIITA) and consecutively increased MHCII-levels on DCs. Inhibition of JAK1/2 or CIITA knockdown in DCs prevented miR-146a-/- DC-induced GVHD exacerbation. Consistent with our findings in mice, patients with the miR-146a polymorphism rs2910164 in hematopoietic cells displayed higher MHCII levels on monocytes, which could be targeted by JAK1/2 inhibition. Our findings indicate that the miR-146a polymorphism rs2910164 identifies patients at high risk for GVHD before allo-HCT. Functionally we show that miR-146a acts as a central regulator of recipient-type DC activation during GVHD by dampening the pro-inflammatory JAK-STAT/CIITA/MHCII axis, which provides a scientific rationale for early JAK1/2 inhibition in selected patients.
引用
- Stickel N, Hanke K, Marschner D, et al. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia. 2017. PMID: 28484267. doi:10.1038/leu.2017.137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。